Stock Movers Apple and Intel Soar on Tariff Pause; Pfizer Down on Obesity Drug Pivot
Apr 14, 2025
Intel is on the rise thanks to a pause in US tariffs on chips, and an upcoming stake sale could boost its programmable chips unit. Apple shares are climbing as analysts remain bullish, eyeing a $225 price target amid tech tariff exemptions. On the flip side, Pfizer's stock takes a hit as it abandons its obesity drug due to safety concerns, redirecting funds to earlier treatments. Meanwhile, Comcast faces a downgrade, highlighting the volatile nature of the current market.
AI Snips
Chapters
Transcript
Episode notes
Chip Stocks Soar on Tariff Pause
- Several chip-exposed companies, including Intel and Micron, are rallying due to a pause in US tariffs on chips and tech.
- Apple is also up on the news, and analyst Laura Martin reiterated her Buy position with a $225 price target.
Apple's Tariff Resilience
- Apple's high profit margins (43%) suggest it's better positioned to handle the tariffs than other companies.
- The tariff exemption could reduce the negative impact on Apple's stock price.
Pfizer's Obesity Drug Setback
- Pfizer is abandoning its obesity drug, danuglipron, due to safety concerns about potential liver injury.
- This setback impacts Pfizer's competition with Novo Nordisk and Eli Lilly in the weight-loss market.